Increased plasma-soluble fibrin monomer levels in patients with disseminated intravascular coagulation
Open Access
- 1 April 1996
- journal article
- research article
- Published by Wiley in American Journal of Hematology
- Vol. 51 (4) , 255-260
- https://doi.org/10.1002/(sici)1096-8652(199604)51:4<255::aid-ajh1>3.0.co;2-v
Abstract
Plasma‐soluble fibrin monomer (SFM) level in patients with disseminated intravascular coagulation (DIC) was significantly higher than the level in patients with pre‐DIC or in non‐DIC patients, and the level in patients with pre‐DIC was significantly higher than that in non‐DIC patients. There was no significant difference in plasma SFM levels among various diseases underlying DIC. Plasma SFM level in patients with good outcome was significantly decreased after treatment for DIC. The sensitivity of fibrin degradation products and platelet number was high for DIC, but not for pre‐DIC. The sensitivity of thrombin‐antithrombin III complex, plasmin‐plasmin inhibitor complex, and SFM was high for both DIC and pre‐DIC. The specificity of these markers was also high. Receiver operating characteristic analysis suggests that plasma SFM level could be the most useful marker for the diagnosis of both DIC and pre‐DIC.Keywords
This publication has 16 references indexed in Scilit:
- Hemostatic study before onset of disseminated intravascular coagulationAmerican Journal of Hematology, 1993
- A new immunoassay for soluble fibrin enables a more sensitive detection of the activation state of blood coagulation in vivoBlood Coagulation & Fibrinolysis, 1993
- Soluble fibrin as a molecular marker for a pre-thrombotic stateBlood Coagulation & Fibrinolysis, 1993
- Monoclonal antibodies to discrete regions in alpha 2-plasmin inhibitorBlood, 1987
- An immunoassay for human D dimer using monoclonal antibodiesThrombosis Research, 1983
- FOY: [Ethyl -(6-guanidinohexanoyloxy) benzoate] methanesulfonate as a serine proteinase inhibitor. II. effect on coagulo-fibrinolytic system in comparison with heparin or aprotininThrombosis Research, 1981
- FOY: [Ethylp-(6-guanidinohexanoyloxy) benzoate] methanesulfonate as a serine proteinase inhibitor. I. Inhibition of thrombin and factor Xa in vitroThrombosis Research, 1980
- Detection of soluble intermediates of the fibrinogen-fibrin conversion using erythrocytes coated with fibrin monomersBlood, 1976
- Disseminated intravascular coagulation (DIC): An approachThe American Journal of Medicine, 1972
- Heparin treatment for the hemorrhagic diathesis of acute promyelocytic leukemiaThe American Journal of Medicine, 1972